α-Tocopherol induces proatherogenic changes to HDL2 & HDL3: An in vitro and ex vivo investigation

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 392-397

  Wade, Lauren ^a   Nadeem, Nida ^a   Young, Ian S ^a   Woodside, Jayne V ^a   McGinty, Ann ^a   McMaster, Cyril ^a   McEneny, Jane ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Tocopherol; HDL subfractions; Oxidation; PON 1 and LCAT activities

Indexed keywords

ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO;

ADULT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME ISOLATION; EX VIVO STUDY; FEMALE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INTERVENTION STUDY; MALE; NORMAL HUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALPHA-TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; MALE; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; REACTIVE OXYGEN SPECIES;

EID: 84872407659     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.11.032     Document Type: Article

References (30)

1. Bhopal R.S., Rafnsson S.B., Agyemang C., et al. Mortality from circulatory diseases by specific country of birth across six European countries: test of concept. Eur J Public Health 2012, 22:353-359.
2. Poli A., Corsini A. Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials. Eur J Intern Med 2010, 21:372-373.
3. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
4. Nunez-Cordoba J.M., Martinez-Gonzalez M.A. Antioxidant vitamins and cardiovascular disease. Curr Top Med Chem 2011, 11:1861-1869.
5. Nadeem N., Woodside J.V., Kelly S., Allister R., Young I.S., McEneny J. The two faces of alpha- and gamma-tocopherols: an in vitro and ex vivo investigation into VLDL, LDL and HDL oxidation. J Nutr Biochem 2012, 23:845-853.
6. Nojiri S., Daida H., Inaba Y. Antioxidants and cardiovascular disease: still a topic of interest. Environ Health Prev Med 2004, 9:200-213.
7. Arrol S., Mackness M.I., Durrington P.N. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis 2000, 150:129-134.
8. Halliwell B., Rafter J., Jenner A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not?. Am J Clin Nutr 2005, 81:268S-276S.
9. Azzi A., Ricciarelli R., Zingg J.M. Non-antioxidant molecular functions of alpha-tocopherol (vitamin E). FEBS Lett 2002, 22:8-10.
10. Salonen J.T., Nyyssonen K., Salonen R., et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000, 248:377-386.
11. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
12. Hodis N.H., Mackm W.J., LaBree L., et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002, 106:1453-1459.
13. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events ad cancer: a randomized controlled trial. J Am Med Assoc 2005, 293:1338-1347.
14. Raveh O., Pinchuk I., Schnitzer E., Fainaru M., Schaffer Z., Lichtenberg D. Kinetic analysis of copper-induced peroxidation of HDL, auto accelerated and tocopherol-mediated peroxidation. Free Radic Biol Med 2000, 29:131-146.
15. Artl A., Marsche G., Lestavel S., Sattler W., Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000, 20:763-772.
16. Kontush A., de Faria E.C., Chantepie S., Chapman M.J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004, 24:526-533.
17. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
18. Brites F.D., Bonavita C.D., De Geitere C., et al. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000, 152:181-192.
19. McPherson P.A., Young I.S., McKibben B., McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res 2007, 48:86-95.
20. Craft N.E. Carotenoid reversed-phase high-performance liquid chromatography methods: reference compendium. Meth Enzymol 1992, 213:185-205.
21. Hasselwander O., McEneny J., McMaster D., et al. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis 1999, 143:125-133.
22. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788-800.
23. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.
24. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-2531995.
25. Arai H., Uchida K., Fukunaga K., et al. Effect of alpha-tocopherol on the oxidative modification of apolipoprotein E in human very-low-density lipoprotein. Biosci Biotechnol Biochem 2003, 67:402-405.
26. Sakai M., Miyazaki A., Sakamoto Y., Shichiri M., Horiuchi S. Cross-linking of apolipoproteins is involved in a loss of the ligand activity of high density lipoprotein upon Cu(2+)-mediated oxidation. FEBS Lett 1992, 314:199-202.
27. Thomas S.R., Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic Biol Med 2000, 28:1795-1805.
28. Nagano Y., Arai H., Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci U S A 1991, 88:6457-6461.
29. McCall M.R., Tang J.Y., Bielicki J.K., Forte T.M. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol 1995, 15:1599-1606.
30. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersama R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-case mortality. Ann Intern Med 2005, 142:37-46.